<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><description>分享肿瘤领域最新进展，传播正确肿瘤防治理念，提高全社会对肿瘤的关注！新浪微博：@肿瘤资讯</description><managingEditor> (hellodword)</managingEditor><pubDate>Sun, 21 Feb 2021 21:01:46 +0800</pubDate><image><url>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</url><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【2744】良医汇完成亿元融资 持续深度服务肿瘤医生患者</title><link>https://mp.weixin.qq.com/s/6LK6eqK0nYzszCMyWXwNmg</link><description></description><content:encoded><![CDATA[【2744】良医汇完成亿元融资 持续深度服务肿瘤医生患者]]></content:encoded><pubDate>Sun, 21 Feb 2021 18:53:40 +0800</pubDate></item><item><title>新春贺礼！2021 ASCO-GU进展与解读第一弹：肾癌篇</title><link>https://mp.weixin.qq.com/s/qhf5ST1XD1M7XNFlkL5AUA</link><description></description><content:encoded><![CDATA[新春贺礼！2021 ASCO-GU进展与解读第一弹：肾癌篇]]></content:encoded><pubDate>Sun, 21 Feb 2021 18:53:40 +0800</pubDate></item><item><title>丁培荣教授：MDT在左，新技术在右，做好肿瘤患者全程管理</title><link>https://mp.weixin.qq.com/s/8x-vTTotk_BhDnnQ4t_aVA</link><description></description><content:encoded><![CDATA[丁培荣教授：MDT在左，新技术在右，做好肿瘤患者全程管理]]></content:encoded><pubDate>Sun, 21 Feb 2021 18:53:40 +0800</pubDate></item><item><title>【追光者说】吴小华教授丨从NORA研究看PARP抑制剂蓝图</title><link>https://mp.weixin.qq.com/s/zuJiX3X47JgqSLBYiBnVBA</link><description></description><content:encoded><![CDATA[【追光者说】吴小华教授丨从NORA研究看PARP抑制剂蓝图]]></content:encoded><pubDate>Sun, 21 Feb 2021 18:53:40 +0800</pubDate></item><item><title>【2743】李子禹教授：更新诊疗观念，充分发挥肿瘤外科在MDT中的作用</title><link>https://mp.weixin.qq.com/s/BnJFqXUZTYYMYYHcOreUjQ</link><description></description><content:encoded><![CDATA[【2743】李子禹教授：更新诊疗观念，充分发挥肿瘤外科在MDT中的作用]]></content:encoded><pubDate>Sat, 20 Feb 2021 19:48:35 +0800</pubDate></item><item><title>ASCO GU 2021|EV-301研究同步NEJM发表，ADC药物Enfortumab vedotin再次闪耀</title><link>https://mp.weixin.qq.com/s/X0kbpk2RW6kykQeIcOPpJQ</link><description></description><content:encoded><![CDATA[ASCO GU 2021|EV-301研究同步NEJM发表，ADC药物Enfortumab vedotin再次闪耀]]></content:encoded><pubDate>Sat, 20 Feb 2021 19:48:35 +0800</pubDate></item><item><title>2021 ASCO-GI丨林榕波教授点评TASCO1研究：TAS-102+贝伐珠单抗一线治疗无法耐受强烈治疗的不可切除mCRC</title><link>https://mp.weixin.qq.com/s/NBtHKH0BMrMEm221MOObqg</link><description></description><content:encoded><![CDATA[2021 ASCO-GI丨林榕波教授点评TASCO1研究：TAS-102+贝伐珠单抗一线治疗无法耐受强烈治疗的不可切除mCRC]]></content:encoded><pubDate>Sat, 20 Feb 2021 19:48:35 +0800</pubDate></item><item><title>甲醛超标≠致癌</title><link>https://mp.weixin.qq.com/s/JP_Yp-PLJTfKb8owAD5fnw</link><description></description><content:encoded><![CDATA[甲醛超标≠致癌]]></content:encoded><pubDate>Sat, 20 Feb 2021 19:48:35 +0800</pubDate></item><item><title>【2742】牛晓辉教授：坚持多学科诊疗，做好排兵布阵，将药物治疗与外科治疗发挥极致</title><link>https://mp.weixin.qq.com/s/pDUbOSEdAdLp9wdQnwyWiw</link><description></description><content:encoded><![CDATA[【2742】牛晓辉教授：坚持多学科诊疗，做好排兵布阵，将药物治疗与外科治疗发挥极致]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授点评：术前mFOLFIRINOX联合或不联合放疗用于胰腺交界性可切除腺癌的疗效</title><link>https://mp.weixin.qq.com/s/r8i4mueapc10kzv60dG1kA</link><description></description><content:encoded><![CDATA[【2021 ASCO-GI】林榕波教授点评：术前mFOLFIRINOX联合或不联合放疗用于胰腺交界性可切除腺癌的疗效]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>“GIST 新时空”专栏 | 赵传华教授解析：全面的NGS检测在GIST分子诊断中的应用</title><link>https://mp.weixin.qq.com/s/ofPnLTmxICG11lanA9QR0A</link><description></description><content:encoded><![CDATA[“GIST 新时空”专栏 | 赵传华教授解析：全面的NGS检测在GIST分子诊断中的应用]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>【用“实例”说话】巨块型肝癌伴微血管癌栓，多学科诊疗使患者获得长生存</title><link>https://mp.weixin.qq.com/s/DlCBx9pHhvd6-C4j4xWzng</link><description></description><content:encoded><![CDATA[【用“实例”说话】巨块型肝癌伴微血管癌栓，多学科诊疗使患者获得长生存]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>世界癌症负担数据| 这四种因素与癌症关系太紧密了！</title><link>https://mp.weixin.qq.com/s/ki1UvgF3y2c1cAvENk1RyA</link><description></description><content:encoded><![CDATA[世界癌症负担数据| 这四种因素与癌症关系太紧密了！]]></content:encoded><pubDate>Fri, 19 Feb 2021 18:51:44 +0800</pubDate></item><item><title>【2741】陈晓红教授：坚守初心，做好角色担当，打造核心竞争力</title><link>https://mp.weixin.qq.com/s/p8DuMWph31v6R_twcYWVlg</link><description></description><content:encoded><![CDATA[【2741】陈晓红教授：坚守初心，做好角色担当，打造核心竞争力]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>陈功教授|国内首个微卫星不稳定检测试剂盒获批，开创MSI检测“有证”时代！</title><link>https://mp.weixin.qq.com/s/adhghZemj2Tn5Wv8PgfABQ</link><description></description><content:encoded><![CDATA[陈功教授|国内首个微卫星不稳定检测试剂盒获批，开创MSI检测“有证”时代！]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授：Infigratinib治疗FGFR2基因融合/重排的晚期胆管癌，疗效可期</title><link>https://mp.weixin.qq.com/s/U_zd-FxiPSgxLgDMkzBAtQ</link><description></description><content:encoded><![CDATA[【2021 ASCO-GI】林榕波教授：Infigratinib治疗FGFR2基因融合/重排的晚期胆管癌，疗效可期]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>在我们身边的致癌物，内附IARC公布的121种I类致癌物名单</title><link>https://mp.weixin.qq.com/s/gSdc8S5O9FCIGQq_pbKLgg</link><description></description><content:encoded><![CDATA[在我们身边的致癌物，内附IARC公布的121种I类致癌物名单]]></content:encoded><pubDate>Thu, 18 Feb 2021 18:57:05 +0800</pubDate></item><item><title>【2740】周志伟教授：多学科携手新技术，助力肿瘤患者获益最大化</title><link>https://mp.weixin.qq.com/s/XiAvT1gexTbwvTXXDk29JA</link><description></description><content:encoded><![CDATA[【2740】周志伟教授：多学科携手新技术，助力肿瘤患者获益最大化]]></content:encoded><pubDate>Wed, 17 Feb 2021 19:14:18 +0800</pubDate></item><item><title>【2021 ASCO-GI】林榕波教授点评ClarIDHy研究：Ivosidenib为IDH1突变型晚期胆管癌治疗添生机</title><link>https://mp.weixin.qq.com/s/ylZy_2EybvbEuhglwpRVRA</link><description></description><content:encoded><![CDATA[【2021 ASCO-GI】林榕波教授点评ClarIDHy研究：Ivosidenib为IDH1突变型晚期胆管癌治疗添生机]]></content:encoded><pubDate>Wed, 17 Feb 2021 19:14:18 +0800</pubDate></item><item><title>赵明芳教授：达伯舒®获批一线非鳞非小细胞肺癌适应证，更高可及性惠及更多患者</title><link>https://mp.weixin.qq.com/s/r-mQzhvfBwLF5UOXTHn6EA</link><description></description><content:encoded><![CDATA[赵明芳教授：达伯舒®获批一线非鳞非小细胞肺癌适应证，更高可及性惠及更多患者]]></content:encoded><pubDate>Wed, 17 Feb 2021 19:14:18 +0800</pubDate></item></channel></rss>